1. Approximately what percentage of patients with diabetes in the United States are meeting the American Diabetes Association goal hemoglobin A1c level of less than 7%?

2. How much pancreatic β-cell function is already lost at the time of diagnosis for most people with type 2 diabetes mellitus?

3. Which of the following is not a dysfunctional defect that leads to hyperglycemia and type 2 diabetes mellitus?

4. What percentage does the postprandial glucose level contribute to a hemoglobin A1c level less than 7.3%?

5. According to the American Diabetes Association, which of the following is not listed as a second-line (dual therapy) treatment option?

6. Insulin “fixes” dysfunctional defects in which of the following cells/tissues?

7. Which of the following is NOT a long acting basal insulin?

8. Which of the following glucagon-like peptide-1 receptor agonists is a short-acting agent?

9. Patients injecting premixed insulin (containing an intermediate-acting insulin and a short-acting insulin) twice daily (before breakfast and before supper) are at greatest risk for hypoglycemia at what time of day?

10. Which of the following oral diabetes therapies has a high risk of hypoglycemia and promotes weight gain?

« Return to Activity